Clinical features and treatment of COVID-19 patients in northeast Chongqing

Suxin Wan, Yi Xiang, Wei Fang, Yu Zheng, Boqun Li, Yanjun Hu, Chunhui Lang, Daoqiu Huang, Qiuyan Sun, Yan Xiong, Xia Huang, Jinglong Lv, Yaling Luo, Li Shen, Haoran Yang, Gu Huang, Ruishan Yang, Suxin Wan, Yi Xiang, Wei Fang, Yu Zheng, Boqun Li, Yanjun Hu, Chunhui Lang, Daoqiu Huang, Qiuyan Sun, Yan Xiong, Xia Huang, Jinglong Lv, Yaling Luo, Li Shen, Haoran Yang, Gu Huang, Ruishan Yang

Abstract

The outbreak of the novel coronavirus in China (SARS-CoV-2) that began in December 2019 presents a significant and urgent threat to global health. This study was conducted to provide the international community with a deeper understanding of this new infectious disease. Epidemiological, clinical features, laboratory findings, radiological characteristics, treatment, and clinical outcomes of 135 patients in northeast Chongqing were collected and analyzed in this study. A total of 135 hospitalized patients with COVID-19 were enrolled. The median age was 47 years (interquartile range, 36-55), and there was no significant gender difference (53.3% men). The majority of patients had contact with people from the Wuhan area. Forty-three (31.9%) patients had underlying disease, primarily hypertension (13 [9.6%]), diabetes (12 [8.9%]), cardiovascular disease (7 [5.2%]), and malignancy (4 [3.0%]). Common symptoms included fever (120 [88.9%]), cough (102 [76.5%]), and fatigue (44 [32.5%]). Chest computed tomography scans showed bilateral patchy shadows or ground glass opacity in the lungs of all the patients. All patients received antiviral therapy (135 [100%]) (Kaletra and interferon were both used), antibacterial therapy (59 [43.7%]), and corticosteroids (36 [26.7%]). In addition, many patients received traditional Chinese medicine (TCM) (124 [91.8%]). It is suggested that patients should receive Kaletra early and should be treated by a combination of Western and Chinese medicines. Compared to the mild cases, the severe ones had lower lymphocyte counts and higher plasma levels of Pt, APTT, d-dimer, lactate dehydrogenase, PCT, ALB, C-reactive protein, and aspartate aminotransferase. This study demonstrates the clinic features and therapies of 135 COVID-19 patients. Kaletra and TCM played an important role in the treatment of the viral pneumonia. Further studies are required to explore the role of Kaletra and TCM in the treatment of COVID-19.

Keywords: COVID-19; clinical features; cognition; northeast Chongqing; treatment.

Conflict of interest statement

The authors declare that there are no conflict of interests.

© 2020 Wiley Periodicals, Inc.

Figures

Figure 1
Figure 1
The epidemiology of the included COVID‐19 patients. COVID‐19, coronavirus disease
Figure 2
Figure 2
The character of the chest computed tomography (CT) scan in new coronavirus pneumonia patients. The letter “l” stands for “lung window”, and “m” stands for “mediastinal window”. The CT images were obtained at both lung and mediastinal window settings, showing the multiple patchy ground‐glass density shadows on each leaf of the lungs, without bronchial obstruction and pleural effusion

References

    1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497‐506.
    1. World Health Organization . Clinical management of severe acute respiratory infection when novel coronavirus (2019‐nCoV) infection is suspected: interim guidance, 28 January 2020. World Health Organization. 2020.
    1. General Office of the National Health and Family PlanningCommission . Diagnosis and treatment of novel coronavirus pneumonia (trial version 5). Chin J Integr Med. 2020;3.
    1. Wang F, Sun YG, Yin W, et al. Effects of matrine combied with baicalin on mouse pneumonia induced by LPS. Chin Pharmacol Bull. 2018;8:1105‐1109.
    1. Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. BioSci Trends. 2020;14(1):64‐68.
    1. Guan W, Ni Z, Hu Y, et al. Clinical characteristics of 2019 novel coronavirus infection in China. medRxiv. 2020.
    1. Phan LT, Nguyen TV, Luong QC, et al. Importation and human‐to‐human transmission of a novel coronavirus in Vietnam. N Engl J Med. 2020;382:872‐874.
    1. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020.
    1. Yu P, Zhu J, Zhang Z, Han Y, Huang L. A familial cluster of infection associated with the 2019 novel coronavirus indicating potential person‐to‐person transmission during the incubation period. J Infect Dis. 2020.
    1. Assiri A, Al‐Tawfiq JA, Al‐Rabeeah AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis. 2013;13:752‐761.
    1. Müller NL, Ooi GC, Khong PL, Nicolaou S. Severe acute respiratory syndrome: radiographic and CT findings. Am J Roentgenol. 2003;181:3‐8.
    1. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507‐513.
    1. Wan S, Yi Q, Fan S, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). medRxiv. 2020.
    1. Kim JY, Choe PG, Oh Y, et al. The first case of 2019 novel coronavirus pneumonia imported into Korea from Wuhan, China: implication for infection prevention and control measures. J Korean Med Sci. 2020;35(5):e61.
    1. Lim J, Jeon S, Shin H‐Y, et al. Case of the index patient who caused tertiary transmission of COVID‐19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID‐19 infected pneumonia monitored by quantitative RT‐PCR. J Korean Med Sci. 2020;35(6):e79.
    1. He L, Ding Y, Zhang Q, et al. Expression of elevated levels of pro‐inflammatory cytokines in SARS‐CoV‐infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS. J Pathol. 2006;210:288‐297.
    1. Wong C, Lam C, Wu A, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004;136:95‐103.
    1. Falzarano D, De Wit E, Rasmussen AL, et al. Treatment with interferon‐α2b and ribavirin improves outcome in MERS‐CoV‐infected rhesus macaques. Nature Med. 2013;19:1313‐1317.
    1. Faure E, Poissy J, Goffard A, et al. Distinct immune response in two MERS‐CoV‐infected patients: can we go from bench to bedside? PLoS One. 2014:9 e88716.
    1. Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019‐nCoV pneumonia. Lancet. 2020;395:683‐684.
    1. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3:e343.
    1. Chen RC, Tang XP, Tan SY, et al. Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest. 2006;129:1441‐1452.
    1. Zhao J, Hu Y, Du RH, et al. Expert consensus on the use of corticosteroid in patients with 2019‐nCoV pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43:E007.
    1. Luo Y, Wang C‐Z, Hesse‐Fong J, Lin J‐G, Yuan C‐S. Application of Chinese medicine in acute and critical medical conditions. Am J Chin Med. 2019;47:1223‐1235.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅